Also TNFR2 agonism in T1D is unique in expansion to create homogenous populations of these desired Treg cells unlike the standard protocols of anti-CD3 plus anti-CD28, IL2 and rapamycin that expand but as demonstrated in Figure 5d, expand heterogenous CD4 cells populations, not only highly activated Tregs. The gene discussed is TNFRSF1B; the disease is type 1 diabetes mellitus.